Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities GlobeNewswire - Wed May 20, 3:05PM CDT

MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update GlobeNewswire - Wed May 13, 3:05PM CDT

On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS) GlobeNewswire - Mon May 11, 8:10AM CDT

Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment,...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) GlobeNewswire - Fri May 8, 3:05PM CDT

MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026 GlobeNewswire - Tue May 5, 3:15PM CDT

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) GlobeNewswire - Wed Apr 8, 8:15AM CDT

The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs,...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update GlobeNewswire - Tue Mar 17, 3:05PM CDT

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 GlobeNewswire - Thu Mar 12, 8:00AM CDT

MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Closing of Private Placement of up to $30 Million GlobeNewswire - Wed Mar 11, 3:05PM CDT

$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market...

LGVN : 0.7600 (-1.30%)
LGVNR : 0.0005 (-37.50%)
A glass jar full of pennies_ Image by John Brueske via Shutterstock_
A $30 Million Reason to Buy Penny Stock Longeveron Today Barchart - Wed Mar 11, 8:00AM CDT

Longeveron shares rip higher as the biotech firm raises $30 million via a private placement. Here’s why it may not be too late to invest in LGVN stock yet.

LGVN : 0.7600 (-1.30%)

Barchart Exclusives

Despite Positive Developments, Rocket Lab Stock Is a High-Risk Name Barchart - 1 hour ago
Rocket Lab is having trouble with a key rocket. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.